ClinicalTrials.gg
RecruitingNCT07494409Updated Mar 27, 2026

A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia

A Phase 3 interventional study of AND017 capsules and ESA in Anemia Due to Chronic Kidney Disease, sponsored by Kind Pharmaceuticals LLC. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Kind Pharmaceuticals LLC · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Oct 2025, registered Mar 2026).
  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 115 studies in Anemia with a site in China — 33 open to participants now, 42 under way, 8 of them phase 3. Anemia · China.

Planned enrollment
21st of 97
300 · median 120
Started
2025
with 14 others
Phase 3
22 of 115
2 open now
Primary completion
2026-10
later than 18 of 41 live
Registered
111th of 115
by date
Lead sponsor
4 of 115
Kind Pharmaceuticals LLC

Among the 115 studies in Anemia with a site in China, this one is the 21st largest by planned enrollment of the 97 interventional ones that give a count, is one of 15 that started in 2025, is one of 22 in phase 3, reaches primary completion later than 18 of the 41 other live ones, and was the 111th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

33 of the 115 studies in Anemia with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Anemia with a site in China, or all of them as a file.
02

Study summary

This is a phase III, randomized, open-label, active-controlled study to evaluate the safety and efficacy of AND017 in anemic patients with End-Stage-Kidney-Disease (ESKD)

03

Conditions studied

  • Anemia Due to Chronic Kidney Disease

Browse trials for

Keywords

  • anemia
  • CKD
  • ESKD
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Receiving stable hemodialysis (including combination methods such as hemodiafiltration or hemofiltration), peritoneal dialysis for ESKD for a minimum of 16 weeks prior to randomization and determined by the Investigator to be compliant with dialysis treatment prescription.
  • Patient must have been on IV or SC of an approved ESA under the prescription for at least 6 weeks
  • The mean of two values during screening must be 9.0-12.0 g/dL.
  • (AST) and alanine aminotransferase (ALT)\<3× (ULN)
  • Transferrin saturation ≥20% or ferritin ≥100 ng/mL at screening test
  • Serum folate and vitamin B12 ≥ lower limit of normal (LLN) at screening test

Key Exclusion Criteria:

  • Concurrent retinal neovascular lesions requiring treatment
  • Chronic inflammatory disease other than glomerulonephritis that could impact erythropoiesis or concurrent disease with inflammatory symptoms
  • History of gastric/intestinal resection considered to affect the absorption of drugs in the gastrointestinal tract or concurrent symptomatic gastroparesis despite being on treatment
  • Uncontrolled hypertension, defined as patients with hypertension having more than one of three systolic blood pressure >180 mmHg, or diastolic blood pressure >110 mmHg during the screening assessment
  • Concurrent congestive heart failure ( [NYHA] Class III or higher)
  • History of stroke, (TIA), myocardial infarction, thromboembolic event (deep vein thrombosis, DVT), pulmonary embolism, or lung infarction within 24 weeks before the screening assessment
  • Participants with a history of significant liver disease or active liver disease
  • History of a seizure disorder or any occurrence of seizures in the past
  • Serum albumin (ALB) \< 2.5 g/dL at screening test
  • Prior ESA/hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) treatment caused total >1.5xULN, or AST/ALT/ ALP>3xULN, or serious liver disease (acute or active chronic hepatitis, cirrhosis, etc.)
  • Any prior functioning organ transplant or a scheduled organ transplantation, or anephric
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    AND017

    Drug: AND017 capsules

  • Active comparator
    Erythropoiesis Stimulating Agents (ESA)

    Drug: ESA

Interventions

  • AND017 capsules administered orally with a starting dose of 10 mg TIW

  • DrugESA

    ESA injection and dose based on package insert and local practice

06

What researchers measure

Primary outcomes

  1. Evaluate the efficacy of AND017 compared with the active control in maintaining Hb levels in anemic patients with ESKD

    The mean Hb levels averaged over Week 23-27

    Time frame: From Week 23 to Week 27

Secondary outcomes

  1. The percentage of responders

    Responder is defined as: for participants with baseline Hb ≥ 9.0 g/dL, mean Hb ≥10.0 g/dL and a change from baseline ≥ -1.0 g/dL during Weeks 23-27

    Time frame: From baseline to Week 27

  2. Percentage of participants that maintained Hb level over target lower limit

    Percentage of participants with mean Hb ≥ 10.0 g/dL averaged over Weeks 5-27

    Time frame: From Week 5 to Week 27

  3. Maintenance of Hb within 10.0-12.0 g/dL after initial achievement ≥10.0 g/dL during the entire study treatment period.

    During entire study treatment period, the percentage of participants in which Hb, after first reaching ≥ 10.0 g/dL, is maintained within the target range of 10.0-12.0 g/dL (inclusive)

    Time frame: From baseline to Week 53

  4. Incidence of extreme Hb levels of ≥13.0 g/dL or <7.5 g/dL during the entire study treatment period

    During the entire study treatment period, the percentage of participants in which Hb is ≥ 13.0 g/dL or \< 7.5 g/dL

    Time frame: From baseline to Week 53

  5. Incidence of excessive erythropoiesis

    During the entire study treatment period, the percentage of participants with an Hb increase ≥ 1.0 g/dL within any 2-week period and an Hb increase ≥ 2.0 g/dL within any 4-week period respectively

    Time frame: From baseline to Week 53

  6. The cumulative incidence of Hb non-response

    The cumulative incidence of Hb non-response is defined as Hb \< 10.0 g/dL and an increase from baseline \< 1.0 g/dL averaged over Weeks 5-27

    Time frame: From baseline to Week 27

  7. Mean Hb change from baseline averaged over Weeks 5-27

    Mean Hb change from baseline averaged over Weeks 5-27

    Time frame: From baseline to Week 27

  8. Mean Hb change from baseline averaged over Weeks 23-27

    Mean Hb change from baseline averaged over Weeks 23-27

    Time frame: From baseline to Week 27

  9. Mean Hb change from baseline averaged over Weeks 13-17

    Mean Hb change from baseline averaged over Weeks 13-17

    Time frame: From baseline to Week 17

  10. Mean Hb change from baseline averaged over Weeks 27-53

    Mean Hb change from baseline averaged over Weeks 27-53

    Time frame: From baseline to Week 53

  11. Mean Hb change from baseline averaged over Weeks 49-53

    Mean Hb change from baseline averaged over Weeks 49-53

    Time frame: Mean Hb change from baseline averaged over Weeks 49-53

  12. During the entire treatment period, mean Hb at each visit

    During the entire treatment period, mean Hb at each visit

    Time frame: From baseline to Week 53

  13. The use of intravenous iron during the entire study treatment period

    The percentage of participants that have received intravenous iron during the entire study treatment period

    Time frame: From baseline to Week 53

  14. The mean weekly dose of intravenous iron during the entire treatment period

    The mean weekly dose of intravenous iron during the entire treatment period

    Time frame: From baseline to Week 53

  15. The time to first initiation of intravenous iron during the entire treatment period

    The time to first initiation of intravenous iron during the entire treatment period

    Time frame: From baseline to Week 53

07

Study locations

1 of 1 sites recruiting
  • Fudan Univeristy Zhongshan Hospital
    Shanghai, 200032, China
    Recruiting
    • Xiaoqiang Ding · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2026, 11 months after the start.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's planned 11 months is below that.

Counting every sponsor, half of 150 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Mar 27, 2026
StartActual
Oct 31, 2025
Primary completionEst.
Oct 30, 2026
CompletionEst.
Apr 30, 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07494409
Lead sponsor
Kind Pharmaceuticals LLC
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Oct 31, 2025
Primary completion
Oct 30, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Mar 27, 2026

Study contacts

Yusha Zhu, MD, PhD
Contact
yushazhu@kindpharmaceutical.com
6467252552
Yusha Zhu, MD, PhD
study director · Kind Pharmaceuticals LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AND017

Start the discussion